vs
Side-by-side financial comparison of BillionToOne, Inc. (BLLN) and PennyMac Mortgage Investment Trust (PMT). Click either name above to swap in a different company.
PennyMac Mortgage Investment Trust is the larger business by last-quarter revenue ($93.6M vs $83.5M, roughly 1.1× BillionToOne, Inc.). PennyMac Mortgage Investment Trust runs the higher net margin — 56.0% vs 6.8%, a 49.1% gap on every dollar of revenue. On growth, BillionToOne, Inc. posted the faster year-over-year revenue change (117.4% vs -13.3%).
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
PennyMac Mortgage Investment Trust is a U.S.-headquartered real estate investment trust specializing in residential mortgage assets. It invests in performing and non-performing mortgage loans, mortgage-backed securities, and credit risk transfer instruments, operating across investment management and mortgage servicing segments in the U.S. housing market.
BLLN vs PMT — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.5M | $93.6M |
| Net Profit | $5.7M | $52.4M |
| Gross Margin | 69.9% | — |
| Operating Margin | 11.5% | 38.6% |
| Net Margin | 6.8% | 56.0% |
| Revenue YoY | 117.4% | -13.3% |
| Net Profit YoY | 138.3% | 12.5% |
| EPS (diluted) | $0.10 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $93.6M | ||
| Q3 25 | $83.5M | $99.2M | ||
| Q2 25 | — | $70.2M | ||
| Q1 25 | — | $44.5M | ||
| Q4 24 | — | $107.9M | ||
| Q3 24 | $38.4M | $80.9M | ||
| Q2 24 | — | $71.2M | ||
| Q1 24 | — | $74.2M |
| Q4 25 | — | $52.4M | ||
| Q3 25 | $5.7M | $58.3M | ||
| Q2 25 | — | $7.5M | ||
| Q1 25 | — | $9.7M | ||
| Q4 24 | — | $46.5M | ||
| Q3 24 | $-14.9M | $41.4M | ||
| Q2 24 | — | $25.4M | ||
| Q1 24 | — | $47.6M |
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 38.6% | ||
| Q3 25 | 11.5% | 47.4% | ||
| Q2 25 | — | 24.2% | ||
| Q1 25 | — | -14.2% | ||
| Q4 24 | — | 51.1% | ||
| Q3 24 | -32.9% | 32.8% | ||
| Q2 24 | — | 40.2% | ||
| Q1 24 | — | 43.6% |
| Q4 25 | — | 56.0% | ||
| Q3 25 | 6.8% | 58.7% | ||
| Q2 25 | — | 10.7% | ||
| Q1 25 | — | 21.8% | ||
| Q4 24 | — | 43.1% | ||
| Q3 24 | -38.8% | 51.2% | ||
| Q2 24 | — | 35.7% | ||
| Q1 24 | — | 64.2% |
| Q4 25 | — | $0.49 | ||
| Q3 25 | $0.10 | $0.55 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $0.45 | ||
| Q3 24 | $-1.47 | $0.36 | ||
| Q2 24 | — | $0.17 | ||
| Q1 24 | — | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $195.2M | $190.5M |
| Total DebtLower is stronger | $55.0M | $1.1B |
| Stockholders' EquityBook value | $-239.5M | $1.9B |
| Total Assets | $327.5M | $21.3B |
| Debt / EquityLower = less leverage | — | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $190.5M | ||
| Q3 25 | $195.2M | $181.0M | ||
| Q2 25 | — | $108.6M | ||
| Q1 25 | — | $204.2M | ||
| Q4 24 | — | $103.2M | ||
| Q3 24 | — | $102.8M | ||
| Q2 24 | — | $336.3M | ||
| Q1 24 | — | $343.3M |
| Q4 25 | — | $1.1B | ||
| Q3 25 | $55.0M | $299.0M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $968.4M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | — | $5.2B | ||
| Q2 24 | — | $5.4B | ||
| Q1 24 | — | $5.1B |
| Q4 25 | — | $1.9B | ||
| Q3 25 | $-239.5M | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | $-242.9M | $1.9B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | — | $21.3B | ||
| Q3 25 | $327.5M | $18.5B | ||
| Q2 25 | — | $16.8B | ||
| Q1 25 | — | $14.9B | ||
| Q4 24 | — | $14.4B | ||
| Q3 24 | — | $13.1B | ||
| Q2 24 | — | $12.1B | ||
| Q1 24 | — | $12.3B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 0.51× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 2.70× | ||
| Q2 24 | — | 2.76× | ||
| Q1 24 | — | 2.60× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $13.8M | $-7.2B |
| Free Cash FlowOCF − Capex | $6.5M | — |
| FCF MarginFCF / Revenue | 7.7% | — |
| Capex IntensityCapex / Revenue | 8.8% | — |
| Cash ConversionOCF / Net Profit | 2.42× | -137.76× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-7.2B | ||
| Q3 25 | $13.8M | $-1.3B | ||
| Q2 25 | — | $-2.0B | ||
| Q1 25 | — | $-594.3M | ||
| Q4 24 | — | $-2.7B | ||
| Q3 24 | — | $-983.8M | ||
| Q2 24 | — | $243.8M | ||
| Q1 24 | — | $-342.4M |
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -137.76× | ||
| Q3 25 | 2.42× | -22.26× | ||
| Q2 25 | — | -267.53× | ||
| Q1 25 | — | -61.39× | ||
| Q4 24 | — | -58.08× | ||
| Q3 24 | — | -23.76× | ||
| Q2 24 | — | 9.59× | ||
| Q1 24 | — | -7.19× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
PMT
| Other | $55.0M | 59% |
| Interest Rate Sensitive Strategies | $31.4M | 34% |
| Correspondent Production | $7.2M | 8% |
